160 related articles for article (PubMed ID: 10857749)
1. Comparative sequence analysis of the VHL tumor suppressor gene.
Woodward ER; Buchberger A; Clifford SC; Hurst LD; Affara NA; Maher ER
Genomics; 2000 May; 65(3):253-65. PubMed ID: 10857749
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
3. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
[TBL] [Abstract][Full Text] [Related]
5. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
6. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
Iliopoulos O; Ohh M; Kaelin WG
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11661-6. PubMed ID: 9751722
[TBL] [Abstract][Full Text] [Related]
7. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
Takagi Y; Pause A; Conaway RC; Conaway JW
J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
[TBL] [Abstract][Full Text] [Related]
8. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
Zatyka M; Morrissey C; Kuzmin I; Lerman MI; Latif F; Richards FM; Maher ER
J Med Genet; 2002 Jul; 39(7):463-72. PubMed ID: 12114475
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
11. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumour suppressor protein: new perspectives.
Ohh M; Kaelin WG
Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
[TBL] [Abstract][Full Text] [Related]
13. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
Kishida T; Stackhouse TM; Chen F; Lerman MI; Zbar B
Cancer Res; 1995 Oct; 55(20):4544-8. PubMed ID: 7553625
[TBL] [Abstract][Full Text] [Related]
14. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
15. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.
Adryan B; Decker HJ; Papas TS; Hsu T
Oncogene; 2000 Jun; 19(24):2803-11. PubMed ID: 10851083
[TBL] [Abstract][Full Text] [Related]
16. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
18. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.
Stebbins CE; Kaelin WG; Pavletich NP
Science; 1999 Apr; 284(5413):455-61. PubMed ID: 10205047
[TBL] [Abstract][Full Text] [Related]
19. The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
Aso T; Haque D; Barstead RJ; Conaway RC; Conaway JW
EMBO J; 1996 Oct; 15(20):5557-66. PubMed ID: 8896449
[TBL] [Abstract][Full Text] [Related]
20. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]